What is the lead time for production?

The average lead time is 1-3 months for both peak and off-season periods.

Which international markets are served?

Products are exported to over 70 countries, including South America, Southeast Asia, Africa, CIS, Middle East, and Europe.

What is the annual production capacity?

Capacity includes 4 billion tablets, 6 billion capsules, 200 million bags of granules, and 2000 tons of API annually.

Sesitive Antibiotics Amoxicillin and Clavulanate Potassium Tablets 562.5mg

Name: Sesitive Antibiotics Amoxicillin and Clavulanate Potassium Tablets 562.5mg
Brand: Reyoung Pharmaceutical Co., Ltd.
SKU: 1940319102

Shandong, ChinaReyoung Pharmaceutical Co., Ltd.

US$0.15-2.00

20,000 box

Product profile

Customization

Available

Standard

Bp/ USP

Transport Package

10capsules/Blister, 10blister/Box*100/Carton

Specification

50*38*36 CM

Trademark

Reyoung

Origin

China

Production Capacity

2, 000, 000, 000 Per Year

Key features

Broad Spectrum Activity: Combines Amoxicillin and Clavulanate to treat pathogens resistant to Amoxicillin alone via beta-lactamase production.

GMP & ISO Certified: Enterprise authenticated with GMP, ISO9001, ISO14001, and OHS18001 standards for quality assurance.

Global Export Experience: Products exported to over 70 countries including Asia, South America, Africa, CIS, Middle East, and Europe.

Large Production Capacity: Annual capacity includes 4 billion tablets, 6 billion capsules, and 2000 tons of API across multiple formulations.

OEM/ODM Services: Offers custom manufacturing services with 370 R&D engineers and advanced production machinery.

Multiple Certification Passed: Passed GMP inspections in Colombia, Peru, Congo, Ethiopia, Uganda, Nigeria, Ghana, Tanzania, Kenya, and others.

Comprehensive Product Range: Produces 10 categories and over 400 specifications including tablets, capsules, granules, and sterile injections.

Established Manufacturer: Leading pharmaceutical manufacturer in China with over 20 years of international transaction experience.

Company profile

Reyoung Pharmaceutical Co., Ltd.

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2020-10-13 CertifiedNearest Port: Qingdao PortAverage Response Time: ≤24h CertifiedTerms of Payment: LC, T/T, D/P

AI-Powered supplier vetting

SummaryReyoung Pharmaceutical Co., Ltd. is a China-based limited company established in 1998, with 4,950 employees and operations in Shandong. The available information identifies it as a pharmaceutical manufacturer supplying injectable antibiotics, oral solid medicines, veterinary cefotaxime sodium sterile, and lyophilized products. It reports more than 10 production lines, 370 years of combined R&D engineer experience, 50 quality-control staff, and ISO9001, ISO14001, and ISO45001 certifications. Export sales represent 31%–40% of total sales, with exporting reported since 2020 in one record and since 1998 in the company description, creating a discrepancy. Trade records show limited documented transactions and associated buyers in Bolivia, India, and Vietnam. Evidence is insufficient to assess after-sales service, financial credibility, customization, or verified customer performance comprehensively.

Supplier typeThe supplier is identified as a limited company and pharmaceutical manufacturer based in Shandong, China. Its stated products include injectable cephalosporins and penicillins, oral solid medicines, lyophilized products, and veterinary medicines, indicating a combined manufacturing and commercial business profile.

CertificationsThe supplier reports ISO9001:2015, ISO14001:2015, and ISO45001:2016 management-system certificates, along with cGMP, PIC/S, and ANVISA GMP holdings. These claims directly support established quality, environmental, occupational-safety, and pharmaceutical GMP capability, although certificate validity and scope are not independently shown.

R&D capabilityThe supplier reports 370 years of total R&D engineer experience and offers multiple dosage forms and pharmaceutical categories, including lyophilized products and injectable antibiotics. These details support R&D resources and product-development breadth, but no information confirms proprietary technologies, new product launches, patents, or development outcomes.

Production capacityProduction capability is supported by 4,950 employees, more than 10 production lines, pharmaceutical manufacturing descriptions, and product records for injectable antibiotics and veterinary cefotaxime sodium sterile. The plant-area entry is recorded as 0.0m², which is unusable or inconsistent data, so facility scale cannot be confirmed from that field.

Client casesTrade-related records associate the supplier with buyers in Bolivia, India, and Vietnam and show documented transactions for oral rehydration products, cefotaxime acid, and ceftriaxone sodium for injection. The records show some international commercial activity, but the number of stated transactions is limited and no customer testimonials, repeat-order evidence, or performance evaluations are provided.